PHIA Koninklijke Philips N.V.

Leading pathology laboratories deploy tele-diagnostics with Philips during the COVID-19 pandemic

Leading pathology laboratories deploy tele-diagnostics with Philips during the COVID-19 pandemic

November 18, 2020

  • Pathology laboratories around the globe fully digitize tumor tissue samples to maintain the patient diagnostic experience while providing for staff safety
  • Digital transformation modernizes cancer care by enabling telehealth and the use of artificial intelligence (AI) while supporting physicians with integrated oncology informatics

Amsterdam, The Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced leading pathology laboratories across North America, Europe, and Asia have implemented full digitization for their histology samples based on the Philips Digital Pathology scanner and imaging-informatics solutions. Digital images are required to unlock the potential of digital pathology. Remote reviewing of pathological cases is essential to prevent delay in critical patient diagnosis and care, particularly during COVID-19.

During the pandemic, many pathologists, oncologists, and radiologists continued their work from home. This created an unprecedented need for home workstations and secure clinical informatics solutions allowing clinicians to read images remotely and enabling real-time virtual collaboration between their multi-disciplinary care teams. Pre-COVID-19, pathology labs that digitized their workflows across different sites reported and an average .

Examples of leading pathology laboratories that recently transformed towards a digital workflow with Philips IntelliSite Pathology Solution are:  (Canada), Pathology Institute Tel Aviv Sourasky MC (Israel), (Netherlands), St. Olavs Hospital (Norway), (Singapore), (UK), and (UK).

“As healthcare becomes more complex and demanding, digitization has become a key enabler for the hospital to provide better care for our patients and to be more efficient. Digital pathology is an example, and our partnership with companies such as Philips with the clinical and technical know-how is important in helping us achieve our goal,” said Prof. Kenneth Kwek, Chief Executive Officer at Singapore General Hospital SGH.

“COVID-19 has become a catalyst for change – a defining moment for all of us to reimagine healthcare the way it should be,” said , Chief Business Leader, Precision Diagnosis at Philips. ”With a focus on the people at the center of cancer care, we work to innovate workflows, remove barriers of fragmented systems, and bring insights directly to care providers to support excellent cancer care.”

Shared decision-making, pathway selection and treatment

Philips’ solutions for oncology and digital pathology can help transform and enhance the multi-disciplinary workflows, including the oncology tumor board and care pathways process. Critical patient data is integrated for both oncologists, radiologists and pathologists, allowing them to collaborate efficiently, even when working remotely. The Philips platform supports streamlined preparation, enhances review and analysis, and empowers the cancer care team to reach clinical treatment decisions based on disease-specific dashboards, diagnostic images, reports, and structured patient data. Visit for more information on how Philips is enhancing digital pathology workflows. Visit to learn  how Philips integrated workflow solutions connect data, technology and people across the diagnostic enterprise, helping to redefine radiology workflow efficiencies.



For further information, please contact:

Kathy O’Reilly

Philips Global Press Office

Tel.:

E-mail :

Twitter:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at .



Attachments



EN
18/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

MDIC appoints Philips Chief Medical Officer Carla Goulart Peron as new...

MDIC appoints Philips Chief Medical Officer Carla Goulart Peron as new board member April 2, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Carla Goulart Peron, MD, Chief Medical Officer at Philips, has been appointed to the of the Medical Device Innovation Consortium (). Founded in 2012, MDIC is a unique public-private partnership that brings stakeholders across the medical device spectrum together with the US Food and Drug Administration () and other agency partners to help ensure patient access to medical device inn...

 PRESS RELEASE

FDA clears Philips AI solution that provides real-time guidance during...

FDA clears Philips AI solution that provides real-time guidance during complex minimally invasive heart valve repair March 26, 2026 Philips DeviceGuide uses AI to track and visualize mitral valve repair devices [1] in real time during minimally invasive procedures, supporting treatment [2]DeviceGuide integrates with Philips Azurion image-guided therapy platform that combines imaging, real-time data and intelligent software within a unified workflow to support more consistent, efficient and confidently guided minimally invasive procedures Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA...

 PRESS RELEASE

Philips launches IntraSight Plus to simplify coronary interventions an...

Philips launches IntraSight Plus to simplify coronary interventions and advance precision care March 25, 2026 Intuitive interventional cardiology platform combines the most comprehensive set of diagnostic and treatment planning tools to help support confident decisions and improved patient careWith FDA clearance and CE marking, IntraSight Plus streamlines the workflow efficiency of minimally invasive coronary procedures and can enable system operation time savings up to 47% in both the USA and Europe Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technolog...

 PRESS RELEASE

Philips remains No. 1 in Medtech at European Patent Office and the lar...

Philips remains No. 1 in Medtech at European Patent Office and the largest Dutch patent applicant March 24, 2026 Philips ranks No. 1 among medical technology companies in the European Patent Office Technology Dashboard 2025, filing 1,289 patent applications with the EPO in 2025.Philips’ platform-based solutions integrate hardware, software, data and AI to address clinical, operational and everyday health challenges.Philips’ innovation improved the lives of 2 billion people in 2025, with the goal of improving 2.5 billion lives per year by 2030, including 400 million people in medically unde...

 PRESS RELEASE

Philips convenes the Annual General Meeting of Shareholders 2026

Philips convenes the Annual General Meeting of Shareholders 2026 March 23, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has convened the Annual General Meeting of Shareholders (AGM) 2026 and published the agenda with explanatory notes. As previously announced, the agenda includes: Proposal to appoint John DeFord (American, 1962) as new member of the Supervisory Board, with effect from May 8, 2026.Proposals to re-appoint Paul Stoffels (Belgian, 1962), Herna Verhagen (Dutch, 1966) and Sanjay Poonen (American, 1969) as m...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch